Introduction: The incidence of cardiovascular disease (CVD) is now at least three-fold 21 higher in HIV-infected patients as compared with the general population. Although platelet 22 activation and reactivity is implicated in the development of CVDs in HIV infected patients, its 23 precise role remains inconclusive. We aim to assess the association between platelet 24 activation and selected cardiovascular risk factors in HIV-1 infected individuals on highly 25 active anti-retroviral treatment (HAART). 26
Strengths and limitations of this study 52
• This review will comprehensively evaluate published literature on the primary 53 research question, focusing on platelet function in HIV infected individuals on HAART 54 and the risk of cardiovascular disease. 55
• A comprehensive search strategy will be used to identify and retrieve articles relevant 56 to our research question. 57
Introduction 63
The incidence of cardiovascular disease (CVD) (ART) will ultimately commit HIV infected individuals to prolonged ART exposure. The 71 association between highly active anti-retroviral treatment (HAART) and CVDs has been 72 described. Whereby HAART increases platelet reactivity and ultimately increases the risk of 73 developing CVDs [5] . Highly active ART (HAART) is based on protease inhibitors (PIs), 74 which have been shown to exacerbate inflammation and induce insulin resistance [6] . The 75 ongoing activation and exacerbation of inflammation within the immune system has been 76 identified as key driving forces in the pathogenesis of these non-AIDS related deaths [1] . 77
The platelet reactivity index (PRI) is robust measure of the ratio of platelet aggregates in 78 peripheral blood and ratios above 1.05 have been associated with pathological platelet 79 aggregation [5] . Platelets play a role in linking inflammation, chronic immune activation and 80 microvascular dysfunction [7] . The role of platelet activation and increased risk of CVDs in 81 HIV infected patients has been described [8] . However, contradictory findings on activation 82 status of platelets and the risk of CVDs in HIV infected patients have been reported [9] and a 83 clear understanding of the underlying mechanism remains scarce. 84 The benefits of early treatment interventions have been reported, however analysis of data 85 from the large strategies for the management of antiretroviral therapy (SMART) study, 86
showed that markers of inflammation correlated with adverse outcomes in patients on anti-87 retroviral regimens [10] . Moreover, knowledge gained from studies conducted on simian 88 immunodeficiency virus (simian equivalent of HIV) hosts, suggests that chronic immune 89 activation is a key contributor to the pathogenic infection [11] . Therefore, despite adequate 90 control of viral loads in first-world countries, an era of non-AIDS related deaths, such as 91 myocardial infarctions and cerebrovascular accidents (CVAs) now prevails [12] . 92
Furthermore, studies have shown that levels of activated B and T cell lymphocytes remain 93 high in HIV infected individuals despite successful ART [13] In addition, an increase in 94 activated CD8+ T cells after 6 months of suppressive ART is associated with a 1.6-fold 95 increased risk of subsequent death [14] . Persistent T-cell activation induces increased CD4 The systematic review protocol has been prepared according to the PRISMA-P 2015 120
guidelines [16] . Details pertaining the protocol for this systematic review were registered on 121 PROSPERO (PROSPERO number: CRD42017062393) and can be accessed online 122 (https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017062393). 123
124

Eligibility criteria 125
Study design 126
All relevant cross-sectional and case control studies with a clearly defined control population 127 will be included. In addition, randomised controlled trials (RCTs) and retrospective and 128 prospective cohort studies with defined time points highlighting data points before and after 129 intervention will be included. Case studies and case reports will be excluded from the review. 130
131
Participants 132
Studies evaluating platelet function in HIV-1 infected adults defined as 18 years or older will 133 be included. We will include studies that have reported the baseline HIV-1 Viral load and 134 initial CD4 counts and platelet counts of all participants enrolled. In addition, we will also 135 include studies that report the exclusion of participants on non-steroidal anti-inflammatory 136 drugs or aspirin. Studies will be included regardless of the metabolic profile of participants 137 included. Studies that include pregnant women, patients with a known history of malignancy, 138 treatment with anticoagulants will be excluded. 139
140
Interventions 141
We will consider studies that have clearly defined ART or cART initiation of either three or 142 more antiretroviral drugs. Furthermore, we will consider other forms of antiplatelet 143 interventions provided the mode of administration and dose is reported. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Study records 211
Data Management 212
Collection process 213
To minimise data entry errors the web based Eppi-Reviewer software version 4.0, software 214 for research synthesis [17] will be used for data extraction into predefined data forms and 215 exported directly into statistical software. The Mendeley reference manager (version 1.17.10, 216
Mendeley Ltd), will be used to identify duplicates. 217
218
Selection process 219
The selection procedure will be conducted by two independent reviewers (BBN and PVD). 220
Each reviewer will screen the titles, abstracts and full-texts in contrast to the inclusion 221 criteria. The exclusion criteria for title and abstract screening phase will include; 222
Review articles 223
Animal studies or animal models of HIV infection 224
Non HIV-1 related studies 225
The additional criteria will be used for screening full-text 226
Full-text not available 227
2. Duplicate publication of the same study cohort 228
Published conference abstracts 229 230
Data items 231
The following relevant items will be extracted; Author, year, original language, sample size, 232 years of follow-up, outcome measures, patient characteristics (gender ratio, metabolic 233 profile, levels of measured coagulation parameters, platelet counts, levels of immune 234 activation or inflammation, mean CD4 counts HIV-1 RNA levels, duration of infection, 235 duration and type of anti-platelet drugs used, type of cART and dosage administered). 236
In addition, details related to the assays used to measure HIV-1 RNA and platelet function 237 (activation or aggregation) as well as the use of platelet separation techniques (preparation 238 of platelet-rich plasma or platelet poor plasma) will be extracted. In instances where there 239 are no reported data amputation techniques on priority outcomes and when the effect size 240 cannot be calculated, the authors will be contacted for additional data. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   F  o  r  p  e  e  r  r  e  v  i  e  w  o  n  l  y   9 
242
Data simplification 243
Individual studies may report varying dosage of treatment interventions used. To reduce 244 potential bias that may be introduced by multiple comparisons with a single control group 245 these will all be grouped into a single drug specific treatment group. 246
247
Risk of bias in individual studies 248
To assess the potential risk of bias in RCT, information will be collected in accordance to the 249 Cochrane collaboration tool for assessing bias [18] . A judgement on the possible risk of bias 250 of extracted information will be made based on each of the six domains. For observational 251 studies, the relevant domains will be considered these will include participant selection, 252 measurement of variables, confounders and missing data. The judgement will be made 253 independently by two reviewers (ZM and PVD) based on the criteria defined for judging the 254 risk of bias. In an instance of disagreements between the two reviewers, BBN will be 255 consulted for arbitration. 256
257
Data synthesis 258
Assessment of clinical and methodological heterogeneity will be performed first and this will 259 then be followed an assessment of statistical heterogeneity. The Cochran's Q statistic [19] 260 and the I 2 statistics will be used to analyse statistical heterogeneity between studies [20] . If 261 studies show similarity with regards to (participants, intervention, comparisons and 262 outcomes) we will perform a fixed-effect meta-analysis to synthesize similar quantitative 263 data. If efficient number of studies included are homogeneous in terms of extracted 264 information, we will conduct a meta-analysis using R statistical Software (The R foundation 265 for statistical computing, Vienna, Austria). An I 2 value of >25 will be considered as moderate 266 or substantial heterogeneity. The random-effects model will be used should there be 267 significant levels of unexplained statistical heterogeneity [5] . 268
In order to explore the sources of heterogeneity, a subgroup analysis and meta-regression 269 comparing the study estimates from different study-level characteristics which will include, 270 age of the study population, the study design and quality, location of the study and sample 271 size, antiretroviral therapy regimes, aspirin use, reported measure of platelet activation 272 (CD62P, PMAs; sCD40;sCD62P); intervention type (Type of ARV drugs used; type of anti-273 
Cumulative evidence 277
Should there be insufficient homogeneity amongst the selected studies the Cochrane 278 collaboration tool for assessing risk of bias [18] will be used and a qualitative summary of the 279 included studies will be tabulated. To assess the quality and strengths of evidence across 280 selected studies, two independent reviewers (BBN and PVD) will review the studies using 281 the Grading of Recommendations Assessment Development and evaluation (GRADE) 282 approach [21] . The approach will be implemented by downgrading of studies based on 283 several factors such as; study limitations, indirectness of results, publication or reporting 284 bias. The scores will be upgraded for studies with a large effect size and reported adjusting 285 of confounders or not. Ratings for each outcome will be categorised as high, moderate or 286
low. This will then be followed by the rating of the overall quality. The findings will be 287 summarised and presented in the summary of findings table. This research received no specific grant from any funding agency in the public, commercial 295
or not-for-profit sectors. 296
297
Ethics and dissemination 298
This will be a review of existing studies and will not require ethical approval. The findings will 299 be disseminated through peer-reviewed publication and presented at local and international 300
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4
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.
4-6
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.
7
Search 8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).
7-8
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.
7
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.
Risk of bias in individual studies
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.
8
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means).
6
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I
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The search strategy will include medical subject headings (MeSH)
The search will cover literature published between; 1 January 1996 to 30 April 2017. Studies 31 will be independently screened by two reviewers using pre-defined criteria. Relevant eligible 32
full-texts will be screened and data will be extracted and a qualitative synthesis will be 33 conducted. Data extraction will be performed using review manager v5.3. To assess the 34 quality and strengths of evidence across selected studies, the Grading of Recommendations 35 Assessment Development and evaluation (GRADE) approach will be used. The Cochran's Q 36 statistic and the I 2 statistics will be used to analyse statistical heterogeneity between studies. 37
If included studies show high levels of homogeneity a random effects meta-analysis will be 38 performed using R statistical software. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 • A comprehensive search strategy will be used to identify and retrieve articles relevant 56 to our research question. 57
• This will be the first systematic review and meta-analysis aimed at addressing the 58 controversial topic of platelet function in people living with HIV on HAART. 59
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Eligibility criteria 136
Study design 137
All relevant cross-sectional and case control studies with a clearly defined control population 138 will be included. In addition, randomised controlled trials (RCTs) and retrospective and 139 prospective cohort studies with defined time points highlighting data points before and after 140 intervention will be included. Case studies and case reports will be excluded from the review. 141
142
Participants 143
Studies evaluating platelet function in HIV-1 infected adults defined as 18 years or older will 144 be included. We will include studies that have reported the baseline HIV-1 Viral load and 145 initial CD4 counts and platelet counts of all participants enrolled. In addition, we will also 146 include studies that report the exclusion of participants on non-steroidal anti-inflammatory 147 drugs or aspirin. Studies will be included regardless of the metabolic profile of participants 148
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Interventions 153
We will consider studies that have clearly defined HAART regime of either three or more 154 antiretroviral drugs. Furthermore, we will consider other forms of antiplatelet interventions 155 provided the mode of administration and dose is reported. The primary comparators which 156 will relevant for this review will include 157 158
Comparators 159
Comparators will differ based on the study design and will include participants randomised 160 not to receive antiretroviral intervention, participants who are not HIV infected (case-control 161 studies and cohort studies). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Literature searches 205
A search strategy will be developed using medical subject headings (MeSH) words for 206 MEDLINE and this will be adapted to Embase search headings (Emtree) terms for the 207 EMBASE database (supplementary appendix 1). The search terms will also be applied to 208 retrieve studies using the PubMed clinical queries. The electronic database search will be 209
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BMJ Open
The systematic search will be conducted without any language restrictions. The literature 215 retrieved will be restricted to human studies. The search strategy will consist of the following 216 major keywords: Platelets; Platelet P-selectin; Platelet CD40L; Platelet monocyte 217 aggregates; Platelet leukocyte aggregates; Platelet monocyte complexes; HIV-1 infection; 218 and diabetes. For each keyword, multiple synonyms will be searched in the title or abstract. 219 220 221
Study records 222
Data Management 223
Collection process 224
To minimise data entry errors the web based Eppi-Reviewer software version 4.0, software 225 for research synthesis [33] will be used for data extraction into predefined data forms and 226 exported directly into statistical software. The Mendeley reference manager (version 1.17.10, 227
Mendeley Ltd), will be used to identify duplicates. 228
229
Selection process 230
Two independent reviewers (BBN and PVD) will conduct the selection procedure. Each 231 reviewer will screen the titles, abstracts and full-texts in contrast to the inclusion criteria. The 232 exclusion criteria for title and abstract screening phase will include; 233
Review articles 234
Animal studies or animal models of HIV infection 235
Non HIV-1 related studies 236
The additional criteria will be used for screening full-text 237
Full-text not available 238
2. Duplicate publication of the same study cohort 239
Published conference abstracts 240
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Data items 242
The following relevant items will be extracted; Author, year, original language, sample size, 243 years of follow-up, outcome measures, patient characteristics (gender ratio, metabolic 244 profile, levels of measured coagulation parameters, platelet counts, levels of immune 245 activation or inflammation, mean CD4 counts HIV-1 RNA levels, duration of infection, 246 duration and type of anti-platelet drugs used, type of HAART and dosage administered). 247
In addition, details related to the assays used to measure HIV-1 RNA and platelet function 248 (activation or aggregation) as well as the use of platelet separation techniques (preparation 249 of platelet-rich plasma or platelet poor plasma) will be extracted. In instances where there 250 are no reported data amputation techniques on priority outcomes and when the effect size 251 cannot be calculated, the authors will be contacted for additional data. 252
253
Data simplification 254
Individual studies may report varying dosage of treatment interventions used. To reduce 255 potential bias that may be introduced by multiple comparisons with a single control group 256 these will all be grouped into a single drug-specific treatment group. 257
258
Risk of bias in individual studies 259
To assess the potential risk of bias in RCT, information will be collected in accordance to the 260 Cochrane collaboration tool for assessing bias [34] . A judgement on the possible risk of bias 261 of extracted information will be made based on each of the six domains. For observational 262 studies, the relevant domains will be considered these will include participant selection, 263 measurement of variables, confounders, and missing data. The judgement will be made 264 independently by two reviewers (ZM and PVD) based on the criteria defined for judging the 265 risk of bias. In an instance of disagreements between the two reviewers, BBN will be 266 consulted for arbitration. 267
268
Data synthesis 269
Assessment of clinical and methodological heterogeneity will be performed first and this will 270 then be followed an assessment of statistical heterogeneity. information, we will conduct a meta-analysis using R statistical Software (The R foundation 275 for statistical computing, Vienna, Austria). An I 2 value of >25 will be considered as moderate 276 or substantial heterogeneity. The random-effects model will be used should there be 277 significant levels of unexplained statistical heterogeneity [23] . 278
In order to explore the sources of heterogeneity, a subgroup analysis and meta-regression 279 comparing the study estimates from different study-level characteristics. which will include, 280 age, gender of the study population , the study design and quality, location of the study and 281 sample size, antiretroviral therapy regimes, use of statin , use of aspirin, reported measure 282 of platelet activation (CD62P, PMAs; sCD40;sCD62P); intervention type (Type of ARV drugs 283 used; type of anti-hyperglycaemic treatment) and any other important parameters identified 284 during data extraction. 285
286
Cumulative evidence 287
Should there be insufficient homogeneity amongst the selected studies the Cochrane 288 collaboration tool for assessing the risk of bias [34] will be used and a qualitative summary of 289 the included studies will be tabulated. To assess the quality and strengths of evidence 290 across selected studies, two independent reviewers (BBN and PVD) will review the studies 291 using the Grading of Recommendations Assessment Development and Evaluation (GRADE) 292 approach [37] . The approach will be implemented by the downgrading of studies based on 293 several factors such as; study limitations, indirectness of results, publication or reporting 294 bias. The scores will be upgraded for studies with a large effect size and reported adjusting 295 of confounders or not. Ratings for each outcome will be categorised as high, moderate or 296 low. This will then be followed by the rating of the overall quality. The findings will be 297 summarised and presented in the summary of findings table. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
Ethics and dissemination 308
This will be a review of existing studies and will not require ethical approval. The findings will 309 be disseminated through, peer-reviewed publication, local and international conference 310
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METHODS
Eligibility criteria
8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review Pg. 5
Information sources
9 Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage Pg.7
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated Add File 1 Study records:
Data management 11a Describe the mechanism(s) that will be used to manage records and data throughout the review Pg.10 Selection process 11b State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
